Stem Cells Application in Thoracic Surgery: Current Perspective and Future Directions
Two main fields of clinical applications of stem cells in thoracic surgery have been explored: (a) regenerative medicine, that is a branch of translational research in tissue engineering and molecular biology dealing with the replacement, engineering or regeneration of cells, tissues and organs to restore normal function; (b) drug loading and delivery, that is an emerging field proposing stem cells as vectors to deliver anti-cancer agents for targeted therapies.
Bronchopleural fistula is a pathological connection between the bronchus and the pleural cavity that may develop after lung resection, thus causing pleural empyema due to colonization by resident airway bacteria; stem cells and regenerative medicine approach can effectively contribute to impaired bronchial healing, thus preventive a septic and ventilator catastrophe.
In the field of thoracic oncology, MSC are probably one of the best choice for anticancer drug delivery, emerging as potential experimental approach to malignant mesothelioma treatment.
The goal of this review is to focus on clinical applications of stem cell technologies in thoracic surgery, emphasizing regenerative medicine aspects as well as drug loading and delivery in thoracic oncology.
KeywordsDrug loading and delivery Regenerative medicine Stem cells
mesenchymal stromal cells
bone marrow mesenchymal stromal cells
single photon emission computed tomography
positron emission tomography
super paramagnetic iron oxide
ultrasmall superparamagnetic iron oxide
broncho pleural fistula
malignant pleural mesotehlioma
programmed cell death protein 1
The Authors thank Anne Collins for editing the English text.
Conflict of Interest
The authors declare no conflict of interest.
The authors declare that this article does not contain any studies with human participants or animals.
- Aho JM, Dietz AB, Radel DJ, Butler GW, Thomas M, Nelson TJ, Carlsen BT, Cassivi SD, Resch ZT, Faubion WA, Wigle DA (2016) Closure of a recurrent bronchopleural fistula using a matrix seeded with patient-derived mesenchymal stem cells. Stem Cells Transl Med 5(10):1375–1379CrossRefPubMedCentralGoogle Scholar
- Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E (2017) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomized, open-label, phase 1b trial. Lancet Oncol 18:623–630CrossRefPubMedCentralGoogle Scholar
- Cardillo G, Carbone L, Carleo F, Galluccio G, Di Martino M, Giunti R, Lucantoni G, Battistoni P, Batzella S, Dello Iacono R, Petrella L, Dusmet M (2015) The rationale for treatment of postresectional bronchopleural fistula: analysis of 52 patients. Ann Thorac Surg 100(1):251–257. https://doi.org/10.1016/j.athoracsur.2015.03.014CrossRefPubMedGoogle Scholar
- Maio M, Scherpereel A, Calabro L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL (2017) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, doubleblind, placebo-controlled phase 2b trial. Lancet Oncol 18:1261. https://doi.org/10.1016/S1470-2045(17)30446-1CrossRefPubMedPubMedCentralGoogle Scholar
- Pacioni S, D'Alessandris QG, Giannetti S, Morgante L, Coccé V, Bonomi A, Buccarelli M, Pascucci L, Alessandri G, Pessina A, Ricci-Vitiani L, Falchetti ML, Pallini R (2017) Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts. Stem Cell Res Ther 8:53CrossRefPubMedCentralGoogle Scholar
- Petrella F, Spaggiari L (2017) Regenerative medicine in cardiothoracic surgery: do the benefits outweigh the risks? J Thorac Dis. https://doi.org/10.21037/jtd.2017.11.86
- Petrella F, Toffalorio F, Brizzola S, De Pas TM, Rizzo S, Barberis M, Pelicci P, Spaggiari L, Acocella F (2014) Stem cell transplantation effectively occludes bronchopleural fistula in an animal model. Ann Thorac Surg 97(2):480–483. https://doi.org/10.1016/j.athoracsur.2013CrossRefPubMedPubMedCentralGoogle Scholar
- Petrella F, Spaggiari L, Acocella F, Barberis M, Bellomi M, Brizzola S, Donghi S, Giardina G, Giordano R, Guarize J, Lazzari L, Montemurro T, Pastano R, Rizzo S, Toffalorio F, Tosoni A, Zanotti M (2015b) Airway fistula closure after stem-cell infusion. N Engl J Med 372(1):96–97CrossRefGoogle Scholar
- Petrella F, Coccè V, Masia C, Milani M, Salè EO, Alessandri G, Parati E, Sisto F, Pentimalli F, Brini AT, Pessina A, Spaggiari L (2017) Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells. Biomed Pharmacother 87:755–758. https://doi.org/10.1016/j.biopha.2017.01.118CrossRefPubMedGoogle Scholar
- Rizzo S, Petrella F, Zucca I, Rinaldi E, Barbaglia A, Padelli F, Baggi F, Spaggiari L, Bellomi M, Bruzzone MG (2017) In vitro labelling and detection of mesenchymal stromal cells: a comparison between magnetic resonance imaging of iron-labelled cells and magnetic resonance spectroscopy of fluorine-labelled cells. Eur Radiol Exp 1:6. https://doi.org/10.1186/s41747-017-0010-9CrossRefPubMedPubMedCentralGoogle Scholar